Your browser is no longer supported. Please, upgrade your browser.
BLRX BioLineRx Ltd. monthly Stock Chart
BioLineRx Ltd.
Index- P/E- EPS (ttm)-1.97 Insider Own- Shs Outstand21.14M Perf Week-13.26%
Market Cap48.40M Forward P/E- EPS next Y-1.38 Insider Trans- Shs Float19.77M Perf Month54.73%
Income- PEG- EPS next Q-0.27 Inst Own30.87% Short Float12.53% Perf Quarter25.82%
Sales- P/S- EPS this Y40.40% Inst Trans- Short Ratio0.50 Perf Half Y33.92%
Book/sh1.26 P/B1.82 EPS next Y9.20% ROA- Target Price- Perf Year-12.60%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range1.06 - 3.30 Perf YTD1.78%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-30.61% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low115.85% ATR0.25
Employees42 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)54.08 Volatility6.27% 15.08%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.14 Prev Close2.32
ShortableYes LT Debt/Eq- EarningsNov 23 BMO Payout- Avg Volume4.93M Price2.29
Recom1.70 SMA20-3.42% SMA5020.25% SMA20026.96% Volume703,843 Change-1.29%
May-18-17Upgrade Maxim Group Hold → Buy $1 → $3
Feb-13-17Initiated Rodman & Renshaw Buy $3
Aug-12-16Downgrade Maxim Group Buy → Hold $4 → $1
Aug-17-15Reiterated Maxim Group Buy $8 → $4
Jul-27-15Reiterated ROTH Capital Buy $10.50 → $7
Jun-22-15Initiated JMP Securities Mkt Outperform $5
Nov-23-20 08:15AM  
Nov-19-20 10:08AM  
Nov-18-20 07:00AM  
Nov-16-20 10:06AM  
Nov-13-20 09:42AM  
Nov-11-20 10:10AM  
Nov-10-20 10:43AM  
Nov-06-20 10:51AM  
Nov-05-20 09:37AM  
Nov-01-20 08:28AM  
Oct-30-20 09:11AM  
Oct-29-20 08:48AM  
Sep-09-20 10:14AM  
Aug-19-20 07:00AM  
Aug-06-20 07:00AM  
Jul-31-20 07:00AM  
Jul-24-20 01:08PM  
Jul-08-20 08:43AM  
Jul-06-20 08:50AM  
Jul-02-20 08:53AM  
Jun-30-20 10:21AM  
Jun-16-20 10:15AM  
Jun-04-20 07:23PM  
Jun-01-20 08:00AM  
May-29-20 11:46AM  
May-27-20 09:49AM  
May-26-20 08:40AM  
May-20-20 08:00AM  
May-15-20 07:00AM  
Mar-12-20 08:00AM  
Mar-06-20 08:00AM  
Feb-27-20 07:43AM  
Jan-23-20 11:44AM  
Jan-22-20 07:00AM  
Jan-15-20 09:56AM  
Jan-14-20 07:46AM  
Jan-08-20 07:00AM  
Dec-13-19 07:00AM  
Dec-06-19 07:39AM  
Dec-05-19 07:00AM  
Nov-26-19 07:00AM  
Nov-11-19 07:00AM  
Nov-06-19 07:00AM  
Nov-05-19 09:00AM  
Oct-31-19 07:00AM  
Oct-29-19 07:00AM  
Sep-26-19 09:00AM  
Sep-25-19 07:00AM  
Sep-04-19 07:08AM  
Sep-03-19 07:00AM  
Aug-06-19 07:00AM  
Aug-02-19 11:25AM  
Jul-30-19 08:00AM  
Jun-28-19 04:01PM  
Jun-13-19 07:00AM  
May-17-19 09:00AM  
May-14-19 07:00AM  
May-07-19 08:00AM  
May-01-19 08:10AM  
Mar-28-19 07:00AM  
Mar-27-19 03:00PM  
Mar-21-19 08:00AM  
Mar-14-19 07:00AM  
Feb-07-19 01:42PM  
Feb-05-19 11:40AM  
Feb-04-19 05:54PM  
Jan-02-19 09:00AM  
Dec-11-18 07:00AM  
Dec-06-18 07:00AM  
Nov-20-18 08:45AM  
Nov-16-18 08:10AM  
Nov-08-18 07:00AM  
Nov-01-18 08:00AM  
Oct-20-18 01:00PM  
Oct-19-18 07:00AM  
Oct-17-18 08:10AM  
Oct-08-18 10:48AM  
Oct-05-18 08:56AM  
Oct-04-18 04:06PM  
Oct-03-18 06:00AM  
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 and Genentech's TECENTRIQ (Atezolizumab) in Phase 1b/2 studies for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Modi'in, Israel.